Enhancing Lives Worldwide with Ultra-Fine Bubble (UFB) Water
†1 Ultra Fine Bubble: Bubbles less than 1.0 um. It is called “UFB (Ultra Fine Bubble)”. Registered trademark of FBIA (Fine Bubble Industry Association). Our company has obtained permission from the FBIA to use “Ultra Fine Bubble (UFB)”.
SOCIAL ISSUES
There are people who are suffering.
OUR MISSION
Free from daily injections
TOP MESSAGE
The possibilities for UFB water are endless.
Pharstoma Corporation was established with the aim of using UFB water to benefit society to its fullest potential. We hope to greatly improve the lives of people living in our society.
The first target is to turn an injectable drug into an oral drug, which was previously considered impossible, and this will be achieved by taking advantage of the characteristics of UFB.
First, we make oral insulin pills. For diabetics who need insulin therapy, frequent injections are a heavy burden.
Our primary goal is to develop an oral formulation that can be administered by injection and significantly reduce the pain and burden of diabetic patients.
By the way, used needles for insulin injections are classified as home health care waste. They must be taken home even when injected outside the home. Their disposal must follow the rules of the local government. This is a burden for patients and their families. In addition, there is the risk of infection due to needle-stick accidents by cleaning workers. Eliminate all of these concerns by eliminating the millions of used insulin needles that are injected in each home every day.
This is also linked to SDG Goal 12 “Responsibility to Create, Responsibility to Use”. We aim to reduce home healthcare waste.
PEOPLE
Masahiko Kubota
Founder & CEO
Graduated from Keio University, Faculty of Science and Technology
Completed Master’s program in Chemistry, Graduate School of Science and Technology, Keio University
Joined Canon Inc.
Retired after serving as General Manager of the Inkjet Technology Development Center
Over 20 years of R&D work in inkjet printers at Canon Inc.
The discovery and invention of the ink-jet method of generating UFB
Engaged in research and development of UFB water and applied research for 8 years.
Pharstoma Corporation established to explore the possibilities of UFB water
Hideyuki Muto
Founder & Director CFO
Vice President, Creator’s Board, Inc.
B.A. in International Economics, Faculty of Economics, Yokohama National University
Worked in the banking and IT fields, and served as Director and CFO of CHF Corporation before joining the company.
Strong in IT and finance
Mari Kubota
Founder & Director CTO
D., Associate Professor, School of Medicine, Keio University
Graduated from Keio University, Faculty of Science and Technology
Completed Master’s program in Chemistry, Graduate School of Science and Technology, Keio University
Completed Doctoral program in Chemistry, Graduate School of Science and Technology, Keio University
Assistant Professor and Full-time Lecturer, Faculty of Medicine, Keio University before assuming his current position
Adjunct Lecturer, Faculty of Science and Technology, Keio University
Part-time Lecturer, Department of Applied Chemistry, Faculty of Science and Technology, Toyo University
Masato Yasui
Technical Advisor
Professor, Keio University School of Medicine, M.D.
Graduated from Keio University School of Medicine
After serving as a lecturer and assistant professor at Johns Hopkins University School of Medicine in the U.S., became a professor at Keio University School of Medicine
Engaged in research in Life Sciences, Pharmacology and Water Biology
Yoko Matsuzawa
Advisor
Director, Matsuzawa Internal Medicine & Diabetes Clinic
Doctor of Medicine, Certified Specialist, Supervisor, and Council Member of the Japan Diabetes Society
Master’s Degree in Sociology, Graduate School of Social Sciences, Keio University
Bachelor of Medicine, Chiba University
Doctoral Program Graduate, Graduate School of Medicine, Chiba University
Former Vice Chief of the Endocrinology and Diabetes Center, Yokohama Rosai Hospital
Hideki Fujii
Advisor
Professor, Keio University School of Medicine, Ph.D. in Science
Graduated from the Faculty of Science, Hokkaido University
Completed the Doctoral Program in Chemistry, Graduate School of Science, Hokkaido University
After serving as a Research Fellow at the Scripps Research Institute in the United States, a Researcher at the National Institute of Infectious Diseases, an Assistant Professor at Keio University School of Medicine, an Associate Professor at the Graduate School of Medicine, University of the Ryukyus, and a Professor at the Institute of Health Biosciences, the University of Tokushima, currently holds the present position
Engaged in research in immunology, infection immunology, and microbiology
Yasuhiro Bono
Intellectual Property/Contract Patent Office
Position: Director, BONO International Patent Office Patent Attorney (Registration Number: 12738)
Education:
- Bachelor of Engineering, School of Science and Engineering, Waseda University
- Graduate Studies, School of Science and Engineering, Waseda University
Professional Experience:
- Engaged in intellectual property-related work at a major patent office since 1999.
- Passed the Patent Attorney Examination in 2002.
- Established BONO International Patent Office in 2018.
Koichi Terasaka
Collaborative Research Partner
Professor, Doctor of Engineering, Faculty of Science and Engineering, Keio University
Graduated from Keio University Faculty of Science and Engineering
Keio University Graduate School Master’s Program, Graduate School of Science and Engineering, Department of Applied Chemistry, Completed
Completed doctoral course, Graduate School of Science and Engineering, Department of Applied Chemistry, Keio University
Current position after working as assistant, full-time lecturer, assistant professor, and associate professor at Keio University Faculty of Science and Engineering.
Specialty: Chemical engineering (fine bubble)
Director of Fine Bubble Industry Association
Chairman of the Federation of Fine Bubble Societies
DATA
Global Diabetes Market
Type 1 diabetes market size was valued at US$ 7.59 billion in 2022 and is expected to reach US$ 13.64 billion by 2030, growing at a CAGR of 7.6% over the forecast period 2023-2030.
Date May 2022
Type 1 Diabetes Market Size (2023-2030)
Global Diabetes Drug Market
The global diabetes drugs market size was estimated at USD 66 billion in 2023 and is projected to reach approximately USD 118 billion by 2032, growing at a CAGR of 6.67% during the forecast period 2023-2032.
62 million people in the Americas have diabetes
Diabetes is the direct cause of 284,049 deaths each year
North America has the largest market share during the forecast period
Date May 2023
Diabetes Drug Market Size (2022-2032)
Number of Type 1 Diabetes Patients Worldwide
They found that in 2021 there will be approximately 8.4 million T1D patients worldwide, 18% of whom will be under 20 years of age, 64% will be between 20 and 59 years of age, and 19% will be over 60 years of age. In 2021, 500,000 new cases with a median age of onset of 39 years
Type 1 diabetes cases expected to double worldwide between 2021 and 2040
Date Sep 2022
Number of diabetics worldwide
Worldwide, 529 million people (95% uncertainty interval [UI] 500 – 564) live with diabetes
131 million (1.22-1.39) people will have diabetes in 2050
Date Jun 2023
Projected prevalence of type 1 and type 2 diabetes (2000-2040)
CORPORATE
Company name Pharstoma Inc.
Establishment October 2023
Masahiko Kubota, Representative Director
Director Hideyuki Muto
Director Mari Kubota
Address: 105-6415
1-17-1 Toranomon, Minato-ku, Tokyo
Toranomon Hills Business Tower 15F
Representative phone: 03-6807-5976
